A Teva-sponsored study reveals significant care gaps for tardive dyskinesia (TD) among long-term care (LTC) residents. More than half of affected residents don’t receive standard VMAT2i treatment, one-quarter receive no treatment, and misdiagnosis as the broader extrapyramidal syndrome (EPS) is common. This research was based on a retrospective analysis of a database of LTC residents at risk for TD due to antipsychotic drug (APD) or metoclopramide use. The most frequent underlying psychiatric diagnosis for these residents was a mood disorder.
This news highlights a serious concern regarding the well-being of vulnerable LTC residents. The underdiagnosis and inadequate treatment of TD perpetuate a cycle of suffering for these individuals. Accurate diagnosis and appropriate treatment are crucial for managing TD symptoms and improving the quality of life for those affected. This also suggests a need for improved clinician education and awareness about the specific diagnostic criteria and treatment options for TD.
The study found that only 1.1% of residents on APDs received a TD diagnosis, while 5.6% received a broader EPS diagnosis. Less than half of residents with a confirmed TD diagnosis received the recommended VMAT2i treatment. The majority received non-FDA-approved therapies, primarily benztropine. Comorbidities among residents at risk for TD included dementia, chronic pulmonary disease, and congestive heart failure.
This study underscores the need for improved diagnostic practices and treatment protocols within LTC facilities. It calls for a renewed focus on educating healthcare professionals on differentiating TD from other movement disorders and implementing appropriate treatment strategies. Further research and data analysis could elucidate the underlying reasons for the observed care gaps and inform the development of targeted interventions to improve the lives of LTC residents with TD.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
